Rafi Ahmed, PhD, of Emory University, and Thomas F. Gajewski, MD, PhD, of the University of Chicago, received the highest honors from the Cancer Research Institute for their fundamental contributions to the fields of immunology and cancer immunotherapy during the Institute’s 31<sup>st</sup> Annual Awards Dinner on Tuesday, November 14, at The Plaza Hotel in New York City.
Rafi Ahmed, PhD
Rafi Ahmed, PhD
Rafi Ahmed, PhD, of Emory University, and Thomas F. Gajewski, MD, PhD, of the University of Chicago, received the highest honors from the Cancer Research Institute for their fundamental contributions to the fields of immunology and cancer immunotherapy during the Institute’s 31stAnnual Awards Dinner on Tuesday, November 14, at The Plaza Hotel in New York City.
Ahmed, director of the Emory Vaccine Center, a professor in the Department of Microbiology and Immunology, and an investigator at the Emory Center for AIDS research, will receive the 2017 William B. Coley Award for Distinguished Research in Basic Immunology for his seminal work on immune memory, as well as his definitive studies of the role of PD-1 receptor in T cell exhaustion during chronic infection.
Gajewski, leader of the Immunology and Cancer Program, director of the Human Immunologic Monitoring core facility at the University of Chicago Comprehensive Cancer Center, and a professor in the departments of pathology and medicine, will receive the William B. Coley Award for Distinguished Research in Tumor Immunology. Gajewski’s work has enhanced the understanding of the interactions between tumors, immune cells, and other factors that play a role in the immune response to cancer.
Thomas F. Gajewski, MD, PhD
Thomas F. Gajewski, MD, PhD
Each Coley Award honoree will receive a $5,000 prize and a gold medallion bearing the likeness of Coley.
Also during the awards dinner, Shannon J Turley, PhD, will receive the 2017 Frederick W. Alt Award for New Discoveries in Immunology. The award recognizes a former CRI-Irvington postdoctoral fellow whose research has had a major impact on immunology.
Funded by CRI from 2002-2004, Turley is a principal scientist on the cancer immunology team at Genentech, where she focuses on how stromal cells and immune cells influence each other in the context of inflammation, cancer, fibrosis, and response to immunotherapy.
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More
Neoadjuvant Mitomycin C Before TURBT for NMIBC: Safety and Potential Delayed Benefit
April 30th 2025A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.
Read More